extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -23,6 +23,12 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
+
+### Additional Evidence (extend)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-15*
+
+FLOW trial's kidney protection creates the strongest per-patient economic case for GLP-1s because dialysis costs $90K+/year. Slowing eGFR decline by 1.16 mL/min/1.73m2 annually could delay or prevent dialysis for many patients. CKD is among the most expensive chronic conditions to manage. This represents the downstream savings mechanism most favorable to value-based care cost-saving thesis, though no cost-effectiveness analysis was included in the trial publication.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (extend)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-15*
+
+FLOW trial demonstrated cardiovascular death reduction of 29% (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. The cardiovascular benefits emerged as secondary findings in a renal outcomes study, suggesting multi-organ protection is not just additive but potentially synergistic. Separate analysis in Nature Medicine showed additive benefits when used with SGLT2 inhibitors.
+
 ---
 
 Relevant Notes:

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 - FDA indication expansion to T2D patients with CKD (2024)
 - Dialysis cost benchmark: $90K+/year per patient
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-15*
+
+FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), kidney-specific components HR 0.79 (95% CI 0.66-0.94), and annual eGFR slope less steep by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early for efficacy at prespecified interim analysis. FDA subsequently expanded semaglutide (Ozempic) indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM.
+
 ---
 
 Relevant Notes:

entities/internet-finance/colosseum.md

@@ -17,6 +17,7 @@ Colosseum operates Solana's hackathon infrastructure, runs an accelerator progra
 - **2024-03-19** — [[metadao-otc-trade-colosseum]] proposed: $250,000 USDC acquisition of META tokens with 20% immediate unlock and 80% vested over 12 months
 - **2024-03-24** — [[metadao-otc-trade-colosseum]] passed: Colosseum completed OTC acquisition of META tokens from MetaDAO treasury
 
+- **2024-03-19** — Proposed $250k OTC acquisition of META tokens from MetaDAO treasury using conditional TWAP pricing (capped at $850, void above $1,200), with 20% immediate unlock and 80% vesting over 12 months. Included commitment to sponsor MetaDAO in next DAO track hackathon ($50-80k value). Proposal passed 2024-03-24.
 ## Relationship to KB
 - [[metadao]] — strategic investor and ecosystem partner
 - Demonstrates institutional adoption of futarchy-governed token sales as fundraising mechanism

entities/internet-finance/metadao.md

@@ -64,6 +64,7 @@ The futarchy governance protocol on Solana. Implements decision markets through
 - **2023-12-13** — Completed Autocrat v0.1 migration, moving 990,000 META, 10,025 USDC, and 5.5 SOL to new program despite unverifiable build
 - **2024-01-24** — Proposed AMM program to replace CLOB markets, addressing liquidity fragmentation and state rent costs (Proposal CF9QUBS251FnNGZHLJ4WbB2CVRi5BtqJbCqMi47NX1PG)
 - **2024-01-29** — AMM proposal passed with 400 META on approval and 800 META on completion budget
+- **2024-03-19** — Proposal 13: Colosseum OTC trade for up to $250k USDC worth of META tokens, using conditional TWAP pricing with $850 cap and $1,200 void threshold. Executed via 5/7 multisig with 2 Colosseum and 5 MetaDAO members. Proposal passed 2024-03-24. META spot price at proposal: $468.09, circulating supply: 17,421 tokens.
 ## Key Decisions
 | Date | Proposal | Proposer | Category | Outcome |
 |------|----------|----------|----------|---------|

inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md

@@ -7,9 +7,13 @@ date: 2024-05-29
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -38,3 +42,17 @@ Additive benefits when used with SGLT2 inhibitors (separate analysis in Nature M
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Kidney protection is where GLP-1 downstream savings are largest per-patient — dialysis prevention is the economic mechanism most favorable to the VBC cost-saving thesis
 EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for capitated payers, not just the clinical endpoint
+
+
+## Key Facts
+- FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease
+- Median follow-up was 3.4 years before early stopping
+- Trial stopped at prespecified interim analysis due to efficacy
+- Primary composite endpoint showed 24% lower risk with semaglutide (HR 0.76; P=0.0003)
+- Kidney-specific components: HR 0.79 (95% CI 0.66-0.94)
+- Cardiovascular death: HR 0.71 (95% CI 0.56-0.89)
+- Major cardiovascular events: 18% lower risk
+- Annual eGFR slope less steep by 1.16 mL/min/1.73m2 in semaglutide group (P<0.001)
+- FDA expanded semaglutide (Ozempic) indications to include T2D patients with CKD following this trial
+- Dialysis costs approximately $90K+/year per patient
+- Published in New England Journal of Medicine, 2024-05-29